Pepsin and Its Importance for Functional Dyspepsia: Relic, Regulator or Remedy?

Abstract

Background: Functional dyspepsia is a heterogeneous disorder lacking an established therapeutic strategy. Historical treatment attempts with pepsin products were shrugged off, as a simple calculation shows that quantitative substitution is pointless. However, such attempts might have been right for the wrong reason. Summary: Today, the role of pepsins is primarily seen in the provision of signalling amino acids (especially phenylalanine and tryptophan) and peptides, which initiate processes promoting digestion. Proteolysis benefits from pepsin variants showing, contrary to common belief, activities of up to a pH value of 5.0. Non-clinical and clinical studies support the view that liberated amino acids produce a variety of direct and indirect effects. Signal chains stimulated by (mostly aromatic) amino acids lead to secretion of gastrin and cholecystokinin (CCK), mediated, respectively, by CCK2 (gastrin) and Ca²⁺-sensing receptors in the parietal cell, and Ca²⁺-sensing receptors in the antral and duodenal mucosa. Thus, CCK effects such as secretion of pancreatic enzymes and promotion of gastric accommodation are (also) consequential to peptic liberation of amino acids. Key Message: As functional dyspepsia represents a heterogeneous disorder, it may be intriguing to view pepsin as a potential (although still to be proven) treatment modality, distinguished by a diversity of pro-digestive effects.

Unveiling the Immunomodulatory Potential of Phenolic Compounds in Food Allergies

“…The pH of gastric fluids can vary greatly, ranging from two during fasting to as high as six during the ingestion of certain foods. The optimal pH of pepsin is between 1.8 and 3.2, and as such the activity of this enzyme also fluctuates with the pH of the stomach [ 27 ]. The composition of food matrices also plays an important role in the digestion of proteins.…”

Single‐Atom Nanozymes for Catalytic Therapy: Recent Advances and Challenges

“…Historically, therapy represents one of the oldest applications of enzymes, dating back to the end of the 19th century when enzymes like pepsin were utilized to treat dyspepsia. [ 22 ] It is reasonable to argue that the development of enzymatic therapeutics has paralleled biotechnological advancements. [ 23 ] Presently, the industrial market for enzyme‐based drugs is expected to increase at an annual growth rate of 6.5% within the period between 2023–2030.…”